Pretreatment [\(^{18}\text{F}\)]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1

Ewa Burchardt \(^1,2,\)*, Wojciech Burchardt \(^2,3\), Paulina Cegła \(^4\), Anna Kubiak \(^5\), Andrzej Roszak \(^1,2\) and Witold Cholewiński \(^2,4\)

1 Department of Radiotherapy and Oncological Gynecology, Greater Poland Cancer Center, 61-866 Poznan, Poland; andrzej.roszak@wco.pl
2 University of Medical Science Poznan, 61-866 Poznan, Poland; wojciech.burchardt@wco.pl (W.B.); witold.cholewinski@wco.pl (W.C.)
3 Department of Brachytherapy, Greater Poland Cancer Center, 61-866 Poznan, Poland
4 Department of Nuclear Medicine, Greater Poland Cancer Center, 61-866 Poznan, Poland; paulina.cegla@wco.pl
5 Department of Epidemiology, Greater Poland Cancer Center, 61-866 Poznan, Poland; anna.kubiak@wco.pl
* Correspondence: ewa.burchardt@wco.pl

Abstract: Purpose: This study aims to determine whether semiquantitative parameters obtained from both the primary tumor and metastatic pelvic lymph nodes (PLN) diagnosed in fluoro-18-deoxyglucose positron emission tomography (FDG-PET-CT) are associated with disease-free survival (DFS), local control (LC), distant metastasis-free survival (DMFS) and overall survival (OS) in patients with locally advanced squamous cervical cancer (LACC) and metastatic pelvic lymph nodes. Materials: Retrospective analysis was performed on 93 female patients with FIGO IIIC1. The median age was 53 years (27–75). The PET parameters both in the primary tumor and metastatic pelvic lymph nodes, including SUVmax, SUVmean, TLG, MTV, heterogeneity, along with clinical variables, before radical cisplatin-based radiochemotherapy (RCT) were analyzed. The \(p\)-values < 0.05 were considered statistically significant. Results: Median follow-up was 38 months (4.5–92.6). Three years and five years OS were 75% and 70% respectively. Patients with SUVmax above 12.6, SUVmean above 7.6 and with TLG in tumors >245.7 lived longer (\(p\) < 0.05). The higher SUVmax or SUVmean reduced DMFS (HR 0.3 95%CI 0.56–0.96 and 0.59 95%CI 0.37–0.93). The clinical factors and other FDG PET CT parameters were not found to be statistically relevant in terms of OS, DFS, DM and LC. Conclusions: This study is the first report showing that in LACC patient population with PLN involvement treated with definitive RCT, high SUVmean, SUVmax and TLG of the primary tumor in FDG-PET-CT were linked with longer OS. Lower SUVmean and SUVmax were linked with shorter DMFS. None of the clinical factors and the nodal FDG-PET-CT parameters influenced the outcome.

Keywords: positron emission tomography computed tomography; FIGO IIIC1 cervical cancer; squamous cell carcinoma

1. Introduction

According to the World Health Organization (WHO), cervical cancer (CC) continues to be a significant public health problem and the annual number of new cases of CC is expected to increase from 570,000 to 700,000 over the next 12 years (https://www.who.int/reproductive health/topics/cancers/en/, accessed on 9 February 2021). Cervical cancer ranks 4th place in mortality and morbidity worldwide [1]. Still, a lot of newly diagnosed cervical cancer patients are in the inoperable stage. Standard of care in locally advanced cervical cancer (LACC) is radical radiochemotherapy (RCT). In 2018 a new classification of Federation of Obstetrics and Gynecology (FIGO) staging introduced lymph node status as a factor of advanced disease (see Supplementary Materials, FIGO Staging 2018). Patients with positive metastatic lymph nodes below aorta bifurcation (pelvic lymph nodes, PLN)
are classified as stage IIIC1. As accurate staging is crucial in treatment planning and has an impact on prognosis and positron emission tomography/computed tomography with 2-deoxy-2-[\(^{18}\)F]fluoro-D-glucose ([\(^{18}\)F]FDG PET/CT) imaging is recommended before radical treatment (https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf, accessed on 9 February 2021). Response to RCT remains one of the most critical factors associated with local recurrence and overall survival (OS); however, factors associated with failure are poorly known. A more tailored approach based on pre-treatment prediction of recurrence may allow choosing the personalized treatment for patients with more aggressive CC. Different histopathological subtypes and stages can influence treatment outcome even cross the same stage and metabolic results of the [\(^{18}\)F]FDG PET/CT examination. This study aims to determine whether semiquantitative parameters obtained from both the primary squamous cell carcinoma (SCC) tumor and metastatic PLN seen in [\(^{18}\)F]FDG PET/CT are associated with disease-free survival (DFS), local control (LC), distant metastasis-free survival (DMFS) and OS.

2. Materials and Methods

2.1. Patients Characteristic

A retrospective analysis was performed on a group with newly diagnosed, histologically proven CC patients admitted to Department of Radiotherapy and Oncological Gynecology between May 2010 and December 2017. One hundred forty-seven of them were found to have positive distant lymph nodes (LN) and/or paraaortic and/or pelvic lymph nodes in [\(^{18}\)F]FDG PET/CT and ninety-three of them were enrolled in this single-center study. They met the inclusion criteria: PLN below aorta bifurcation, SCC type of cancer, and locally advanced, inoperable disease with definitive RTC treatment. FIGO staging was based on a gynaecological examination with ultrasound imaging performed by two specialists in gynaecology and oncology and represented as follows: IIA-1, IIB-39, IIIA-2, IIIB-48, IVA-3 patients. After the revision of new FIGO staging criteria, all those patients were reclassified in IIIC1. All patients underwent routine clinical assessment, including the recording of medical history reviews, complete blood count, blood chemistry tests. All patients also underwent [\(^{18}\)F]FDG PET/CT for initial diagnosis, staging, and radiotherapy (RT) planning. Patients underwent external beam radiotherapy (EBRT) combined with chemotherapy. RT was administered to the whole pelvic region and lymphatic chain up to aorta bifurcation in 28 fractions of 1.8 Gray (Gy) with a total dose of 50.4 Gy EBRT was delivered in a three-dimensional conformal beams method and concomitant chemotherapy with cisplatin 40 mg/m\(^2\) was administered during RT. The image-guided adaptive intracavitary high dose brachytherapy (BT) with magnetic resonance imaging (MRI) was introduced at the end of treatment. Medical data extracted from computerized medical records included all follow-up data, recurrence, and survival status at the end of the study.

2.2. PET Imaging and Analysis

Scans were acquired on Gemini TF PET/CT scanner (Philips Healthcare Medical Systems, Inc, Cleveland, OH, USA), on average 60–75 min after IV injection of [\(^{18}\)F]FDG with the mean activity of 364 ± 75 MBq. The examination was performed in patients who were fasting for at least five hours before the test (median glucose level: 88 mg%, range 56–160 mg%). The PET/CT imaging was done according to our study protocol in the bed position (1.3 min for one bed position) and cutting scans 5 mm thick. The optimal contouring method was obtained using the 35% SUV\(_{\text{max}}\) (standardized uptake value) threshold and was already verified and described in our previous research [2]. To determine heterogeneity of the primary tumor area under Cumulative SUV-volume histograms the tumor heterogeneity index (AUC-CSH) was used. All PET/CT scans were fused and tumor volumes for cervix and PLN measured using a dedicated workstation in all planes.

The selected ROI (region of interest) was manually adjusted by visual inspection to exclude adjacent FDG-avid structures. Maximum standardized uptake value (SUV\(_{\text{max}}\)),
mean standardized uptake value (SUV$_{\text{mean}}$), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the cervical tumor were recorded during $[^{18}\text{F}]$FDG PET/CT scans. The parameters were calculated as follows: SUV = radioactivity of the sensitive area/weight, SUV$_{\text{max}}$ was the maximum SUV in the ROI, MTV was the volume included in the curve bigger than or equal to Th35% SUV$_{\text{max}}$, SUV$_{\text{mean}}$ was the mean SUV in the MTV, and TLG was calculated as SUV$_{\text{mean}}$ × MTV. Beside parameters for primary tumor, we also assessed parameters which include the sum of values from primary tumor and metastatic PLN: TLG$_{\text{total}}$, SUV$_{\text{total}}$ and MTV$_{\text{total}}$ (Figure 1).

**TUMOR PARAMETERS EVALUATED IN 18F-FDG-PET/CT**

MTV – Metabolic Tumor Volume
SUV$_{\text{max}}$
SUV$_{\text{mean}}$
TLG – Total Lesion Glycolysis
TLG = MTV × SUV$_{\text{mean}}$

$\text{TLG}_{\text{TOTAL}} = \Sigma (\text{MTV} \times \text{SUV}_{\text{mean}})$

**Figure 1.** Tumor parameters evaluated in 18F-FDG-PET/CT.

2.3. **Follow-Up**

Follow-up included a clinical examination every three months for the first two years and every six months for the following three years or longer. Imaging (MRI, computed tomography CT, PET/CT, vaginal ultrasound) complementary to the clinical examination was performed as part of the follow-up. The last date of follow up was September 2019, but survival data were verified in Regional Cancer Registry and the National Cancer Registry (NCR) on the date December 2018.

2.4. **Statistical Analysis**

All data were gathered in the MS Excel spreadsheet, and descriptive statistics were developed. DFS was defined as the time from the start of treatment to the date of the first clinical or imaging findings that suggested disease recurrence: either distant metastasis or local relapse. Both local recurrence and systemic failure were defined as the time from the start of treatment to the day of local/systemic relapse recognized in an examination and imaging and/or proven by biopsy. OS was defined as the time from the start of treatment to death. The continuous variables cervical and lymph nodes metabolic parameters were dichotomized at the median and the Kaplan-Meier method was used in the survival analysis, and the F cox test was used as a comparison test of two groups. If the F Cox test was inappropriate log rang test was used. The Cox proportional hazard model was used to evaluate prognostic variables. Statistical analyses were performed with Statistica 12 software (StatSoft Inc.), and $p$-values <0.05 were considered statistically significant.
3. Results

Ninety-three patients were included in the study. The median age was 53 years at diagnosis (range 27–75 y), the median BMI was 26 (range 12.4–37.9) and the median time of hospitalization was 58 days (range 31–90). The included patients had a biopsy with proven SCC. Median total dose (TD) for the primary tumor was 50 Gy with EBRT (range 45–50.4 Gy) and 28 Gy (range 14–28 Gy) with BT. Median TD for not active in $^{18}$F]FDG PET imaging PLN was 50.4 Gy (range 45–50.4 Gy). Positive PLN were boosted in 49 cases. Median cisplatin courses were 4 (range 1–7) (Table 1).

Table 1. Patient characteristics.

|                      | n     | %   | Average | Median | Min | Max  | SD  |
|----------------------|-------|-----|---------|--------|-----|------|-----|
| Age (Years)          | 93    | 100.0 | 52.4    | 52.9   | 27.5 | 74.8 | 10.0 |
| BMI                  | 88    | 94.6 | 26.2    | 25.95  | 12.4 | 37.9 | 5.5  |
| FIGO Stage           |       |      |         |        |     |      |     |
| IIA                  | 1     | 1.1  |         |        |     |      |     |
| IIB                  | 39    | 41.9 |         |        |     |      |     |
| IIIA                 | 2     | 2.2  |         |        |     |      |     |
| IIIB                 | 48    | 51.6 |         |        |     |      |     |
| IV                   | 3     | 3.2  |         |        |     |      |     |
| Length of Hospitalization (Days) | 93 | 100.0 | 58.1    | 58     | 31  | 90   | 10.6 |
| SCC Grade            |       |      |         |        |     |      |     |
| G1                   |       |      |         | 4.2    | 4   | 1    | 1.2  |
| G2                   | 48    | 100.0 | 50.0    | 50.4   | 45  | 50.4 | 1.0  |
| G3                   | 19    | 26.2 | 10.1    | 10     | 8   | 19   | 1.6  |
| n.d.                 | 23    |      | 26.9    | 28     | 14  | 28   | 3.1  |
| Chemotherapy Courses | 93    | 100.0 | 43.0    | 43.0   | 38  | 92.6 | 23.6 |
| TD for Elective LN   | 93    | 100.0 | 50.0    | 50.4   | 45  | 50.4 | 1.0  |
| TD for Primary       | 93    | 100.0 | 47.9    | 50     | 45  | 50.4 | 2.6  |
| Boost with EBRT for LN+ (Gy) |     |      |         |        |     |      |     |
| Yes                  | 49    | 52.6 | 10.1    | 10     | 8   | 19   | 1.6  |
| No                   | 44    | 47.4 |         |        |     |      |     |
| Brachytherapy        | 93    | 100.0 | 26.9    | 28     | 14  | 28   | 3.1  |
| Follow-Up            | 93    | 100.0 | 43.0    | 43.0   | 38  | 92.6 | 23.6 |

BMI: Body Mass Index, FIGO: International Federation of Gynecology and Obstetrics Staging System, SCC: squamous cervical carcinoma, TD: total dose, LN: lymph node, EBRT: external beam radiotherapy, Gy: gray, n: number, SD: standard deviation.

Median follow-up was 38 months (range 4.5–92.6). A total of 73% of patients were alive (Figure 2A). Estimated 3-year and 5-year OS were 75% and 70%, respectively. Local recurrence was observed in 14 cases, 5 of them are still alive. Estimated 3-year and 5-year LC was 82.2% and 80.9% respectively, based on examination and imaging (Figures 2B, 3A,B and 4A,B). Distant metastases were observed in six cases; two of them are still alive. A total of 87% developed no systemic failure. Two patients had both local failure and distant metastases diagnosed at the same time.
control and without any oncological symptoms two months earlier in ambulatory control visit).

**Figure 2.** Kaplan-Meier graphs presenting the cumulative proportion of overall survival (A), local control (B), disease-free survival (C), distant metastasis-free survival (D) in patients with cervical cancer and positive metastatic pelvic lymph nodes treated with radical radiochemotherapy.

**Figure 3.** (A) $^{18}$F-FDG PET image shows FDG uptake by tumor in the cervix (arrow). (B) $^{18}$F-FDG PET image shows no FDG uptake in the cervix (arrow).
All patients showed an increased $[^{18}F]$FDG uptake in the cervical tumors detected at PET/CT ($n = 93$). In this group, semiquantitative $[^{18}F]$FDG parameters for the cervical tumor SUV$_{max}$, SUV$_{mean}$, MTV, and TLG were 12.89 (range 4.56–32.61); 7.59 (range 2.58–17.93); 34.01 mL (range 7.00–115.25) and 245.64 (range 26.0–1667.7), respectively. The mean AUC-CSH index was 0.58 (range 0.52–0.71) and heterogeneity 0.27 (range 0.17–0.32) (Table 2). FDG PET CT parameters of patients free of disease and FDG PET CT parameters of patients with recurrence are shown in Tables S1 and S2 (see Supplementary Materials).

### Table 2. FGD PET CT parameters.

|                        | $n$ | Average | Median | Min  | Max  | SD   |
|------------------------|-----|---------|--------|------|------|------|
| Activity of FDG (mCi)  | 93  | 8.945   | 8.700  | 4.300| 13.10| 1.747|
| Glucose Level (mg%)    | 93  | 90.914  | 88.000 | 56.000| 160.00| 17.454|
| SUV$_{max}$            | 93  | 14.133  | 12.890 | 4.560| 32.61| 5.510|
| SUV$_{mean}$           | 93  | 8.199   | 7.590  | 2.580| 17.93| 3.188|
| TumorSUV              | 93  | 5076.946| 3869.440| 652.860| 2,6057.90| 4230.602|
| TLG                   | 93  | 322.353 | 245.640| 26.030| 1667.71| 272.469|
| MTV                   | 93  | 37.059  | 34.010 | 7.000| 115.25| 19.791|
| SUV$_{total}$         | 93  | 23.284  | 21.570 | 10.630| 45.10| 8.845|
| TLG$_{total}$         | 93  | 354.185 | 258.840| 45.560| 1769.20| 309.062|
| MTV$_{total}$         | 93  | 40.414  | 38.750 | 8.060| 116.56| 20.280|
| SUV$_{LN}$            | 93  | 9.150   | 7.530  | 1.940| 26.47| 5.716|
| TLG$_{LN}$            | 93  | 31.833  | 7.440  | 0.100| 1667.97| 173.599|

Disease-free survival was observed in 68 cases (71%) (Figure 2C). Twenty-five patients died during follow-up and 11 of them were diagnosed and reported in our ambulatory as oncological reason, either local or systemic failure (Figure 2D). The next seven patients were reported in NCR as death due to cervical cancer, but in the ambulatory control visit 2–3 months earlier, the relapse was not diagnosed. These patients are included in DFS analysis but in neither local control analysis nor in distant metastases analysis. Seven patients died due to non-oncological reasons: bowel perforation ($n = 2$), pancreatitis ($n = 2$), peritonitis ($n = 1$) and two patients without a known reason (with good disease control and without any oncological symptoms two months earlier in ambulatory control visit).

Figure 4. (A) $[^{18}F]$FDG PET image shows FDG uptake by the right pelvic lymph node (arrow). (B) $[^{18}F]$FDG PET image shows no FDG uptake in the right pelvic lymph node (arrow).
Table 2. Cont.

|            | n  | Average | Median | Min   | Max  | SD   |
|------------|----|---------|--------|-------|------|------|
| MTVLN      | 93 | 3.356   | 2.480  | 0.0500| 12.97| 2.783|
| AUC-CSH    | 93 | 0.582   | 0.578  | 0.5170| 0.71 | 0.037|
| Heterogenity| 93 | 0.268   | 0.271  | 0.1710| 0.32 | 0.025|

MTV: metabolic target volume (MTV) of the cervical tumor, MTVLN: MTV obtained from all the metastatic pelvic lymph nodes (PLN), MTVtotal: the sum of MTV of tumor and MTVLN, SD: standard deviation, SUVLN: maximum standardized uptake value of PLN, SUVmax: maximum standardized uptake value of the cervical tumor, SUVmean: mean of standard uptake value of the cervical tumor, SUVtotal: the sum of SUVmax of a tumor and SUVmax obtained from all the metastatic PLN, TLG: total lesion glycolysis of the cervical tumor, TLGLN: total lesion glycolysis obtained from all the metastatic PLN, TLGtotal: the sum of TLG of tumor and TLG obtained from all the metastatic PLN, TumorSUV: the sum of all SUV values.

3.1. Overall Survival Analysis

In the analysis of OS, the patients with SUV$_{\text{max}}$ above 12.6 ($p = 0.01$; Figure 5A), SUV$_{\text{mean}}$ above 7.6 ($p = 0.01$, Figure 5B) and with TLG $\geq$ 245.7 ($p = 0.03$ Figure 5C) lived longer. Patients with SUV$_{\text{max}} \geq$ 12.6 and SUV$_{\text{mean}} \geq$ 7.6 lived 42 months and with SUV$_{\text{max}} < 12.6$ and SUV$_{\text{mean}} < 7.6$ lived 37.9 months.

![Figure 5](image-url)

**Figure 5.** Kaplan-Meier graphs presenting significant differences between the cumulative proportion of overall survival in patients with cervical cancer and positive metastatic pelvic lymph nodes treated with radical radiochemotherapy divided into two groups by (A) median SUV$_{\text{max}}$ 12.6 (F Cox test $p = 0.02$), (B) SUV$_{\text{mean}}$ 7.6 (F Cox test $p = 0.02$), or (C) TLG 245.7 (F Cox test $p = 0.01$).

In other PET parameters, no significant differences were noticed compared to OS. Moreover, in the distant metastases free group, all patients with metastasis had SUV$_{\text{max}} <$ 12.6 and SUV$_{\text{mean}} <$ 7.6 and had shorter time to develop metastasis (Figure 6A,B), which corresponds...
with OS analysis. No differences were observed in analyzed dichotomized $[^{18}\text{F}]$FDG PET parameters between patients with LC or DFS.

**Figure 5.** Kaplan-Meier graphs presenting significant differences between the cumulative proportion of overall survival in patients with cervical cancer and positive metastatic pelvic lymph nodes treated with radical radiochemotherapy divided into two groups by (A) median SUV$_{\text{max}}$ 12.6 (Test log rank, $p < 0.01$), by (B) SUV$_{\text{mean}}$ 7.6 (Test log rank, $p < 0.01$).

Among the $[^{18}\text{F}]$FDG PET/CT pre-treatment parameters in univariate analysis in terms of OS, only SUV$_{\text{max}}$ and SUV$_{\text{mean}}$ were significant parameters (Hazard Ratio (HR) 0.88, 95% confidence interval (95%CI) 0.8–0.97 and HR 0.81, 95%CI 0.69–0.95 $p < 0.05$, respectively (Table 3)). Higher SUV$_{\text{max}}$ and higher SUV$_{\text{mean}}$ were linked with longer survival. The increase in the SUV$_{\text{max}}$ or SUV$_{\text{mean}}$ by one unit was linked with decreased risk of death by 12% and 18% in the whole group, respectively (Table 3). Both variables are correlated together, so they could not be used for multivariate analysis. To show a significant influence on survival in univariate analysis, TLG parameters were dichotomized using a median value of 245.7. Patients with TLG above 245.7 had 60% greater chance of survival in univariate analysis HR 0.4 (95%CI 0.17–0.92, $p < 0.05$).
**Table 3.** Univariate analysis of Cox regression.

| PET Parameters | Death | Metastasis | Progression | Local Recurrence |
|----------------|-------|------------|-------------|------------------|
|                | Hazard Ratio | CI 95% | p Value | Hazard Ratio | CI 95% | p Value | Hazard Ratio | CI 95% | p Value |
| SUVmax         | 0.89   | 0.81–0.98 | 0.01  | 0.73   | 0.56–0.96 | 0.02 | 0.98   | 0.91–1.06 | 0.57 | 1.03   | 0.94–1.13 | 0.50 |
| SUVmean        | 0.81   | 0.69–0.95 | 0.01  | 0.59   | 0.38–0.94 | 0.02 | 0.95   | 0.84–1.09 | 0.47 | 1.04   | 0.89–1.22 | 0.58 |
| TumorSUV       | 1.00   | 1–1       | 0.42  | 1.00   | 1–1       | 0.09 | 1.00   | 1–1       | 0.96 | 1.00   | 1–1       | 0.81 |
| TLG *          | 0.40   | 0.17–0.92 | 0.03  | 0.18   | 0.02–1.57 | 0.12 | 0.95   | 0.43–2.08 | 0.90 | 1.10   | 0.29–4.09 | 0.89 |
| MTV            | 1.00   | 0.99–1.02 | 0.69  | 0.97   | 0.91–1.02 | 0.22 | 1.00   | 0.98–1.02 | 0.78 | 1.00   | 0.98–1.03 | 0.73 |
| SUVtotal       | 0.96   | 0.92–1.01 | 0.13  | 0.97   | 0.88–1.07 | 0.54 | 1.00   | 0.96–1.05 | 0.97 | 2.24   | 0.7–7.14  | 0.17 |
| TLGtotal *     | 0.47   | 0.21–1.07 | 0.07  | -      | -        | -   | 1.00   | 1–1       | 0.75 | 1.01   | 0.96–1.07 | 0.62 |
| MTVtotal       | 1.00   | 0.99–1.02 | 0.65  | 0.97   | 0.92–1.02 | 0.26 | 1.00   | 0.98–1.02 | 0.75 | 1.00   | 0.98–1.03 | 0.71 |
| SUVLN          | 1.00   | 0.93–1.07 | 0.96  | 1.88   | 0.34–10.28| 0.47 | 1.02   | 0.96–1.09 | 0.54 | 1.02   | 0.96–1.09 | 0.54 |
| TLGLN *        | 1.02   | 0.47–2.25 | 0.95  | 1.08   | 0.96–1.22 | 0.20 | 1.06   | 0.48–2.33 | 0.88 | 0.71   | 0.24–2.04 | 0.52 |
| MTVLN          | 1.03   | 0.9–1.18  | 0.65  | 1.06   | 0.82–1.36 | 0.67 | 1.02   | 0.89–1.17 | 0.75 | 1.03   | 0.86–1.23 | 0.75 |
| Heterogeneity **| 1.05   | 0.89–1.23 | 0.57  | 0.96   | 0.71–1.3  | 0.78 | 1.03   | 0.88–1.2  | 0.73 | 0.99   | 0.81–1.22 | 0.93 |
| Age            | 0.99   | 0.95–1.03 | 0.58  | 0.96   | 0.71–1.3  | 0.78 | 1.00   | 0.96–1.04 | 0.90 | 1.00   | 0.95–1.06 | 0.88 |
| FIGO Stage     | 1.37   | 0.91–2.05 | 0.13  | 1.03   | 0.48–2.24 | 0.94 | 1.52   | 1–2.32   | 0.05 | 1.55   | 0.58–4.1  | 0.38 |
| Time of Hospitalization | 0.97 | 0.93–1.01 | 0.19  | 0.98   | 0.91–1.06 | 0.64 | 1.00   | 0.96–1.04 | 0.83 | 0.97   | 0.92–1.02 | 0.24 |
| Tumor Grade    | 2.19   | 0.97–4.95 | 0.06  | 3.90   | 0.68–22.24| 0.13 | 1.43   | 0.59–3.46 | 0.43 | 0.70   | 0.19–2.57 | 0.59 |
| Boost to PLN+  | 0.73   | 0.31–1.7  | 0.46  | 1.31   | 0.27–6.52 | 0.74 | 1.48   | 0.58–3.79 | 0.41 | 1.90   | 0.66–5.51 | 0.23 |
| Chemotherapy Courses | 0.92 | 0.66–1.27 | 0.61  | 1.46   | 0.7–3.03  | 0.31 | 0.99   | 0.71–1.38 | 0.96 | 0.76   | 0.5–1.15  | 0.20 |

CI: confidence interval, FIGO: International Federation of Gynecology and Obstetrics Staging System, HR: hazard ratio, MTV: metabolic target volume (MTV) of the cervical tumor, MTVLN: MTV obtained from all the metastatic pelvic lymph nodes (PLN), MTVtotal: the sum of MTV of tumor and MTVLN; SD: standard deviation, SUVLN: maximum standardized uptake value of PLNSUVmax: maximum standardized uptake value of the cervical tumor, SUVmean: mean of standard uptake value of the cervical tumor, SUVtotal the sum of SUVmax of a tumor and SUVmax obtained from all the metastatic PLN, TLG: total lesion glycolysis of the cervical tumor, TLGLN: total lesion glycolysis obtained from all the metastatic PLN, TLGtotal: the sum of TLG of tumor and TLG obtained from all the metastatic PLN, TumorSUV: the sum of all SUV values within the tumor lesion. * the parameter was dichotomized to the analysis. ** the parameter was 100 times increased to the analysis.
3.2. Distant Metastasis-Free Survival Analysis

Tumor SUV\textsubscript{max} and SUV\textsubscript{mean} were significant parameters in univariate analysis with time to DM. The higher SUV\textsubscript{max} or SUV\textsubscript{mean} reduced the risk of DM (HR 0.73 95%CI 0.56–0.96 and 0.59 95%CI 0.37–0.93), which corresponded with the results from Kaplan-Meier survival analysis (Table 3). Other analyzed \[^{18}\text{F}]\text{FDG PET/CT parameters were not different in terms of distant metastases free survival.}

Three-year distant metastasis-free survival was 92.3%, and 5-year was 89.8%. There was no significant model in the univariate analysis of \[^{18}\text{F}]\text{FDG PET/CT parameters in terms of DFS or LC analysis. The clinical factors (age, grade, FIGO, time of hospitalization, cycles of chemotherapy) were not found to be statistically relevant for the outcome in terms of OS, DFS, DM and LC (p > 0.5, Table 3).}

An example of a woman with stage IIIC1 cervical cancer before and full response after radiochemotherapy.

4. Discussion

The parameters SUV\textsubscript{max}, SUV\textsubscript{mean}, TLG obtained from the primary tumor seen in \[^{18}\text{F}]\text{FDG PET/CT influenced OS. Higher SUV\textsubscript{max}, SUV\textsubscript{mean} of the primary tumor were associated with longer distant metastasis-free survival (DMFS). None of the other PET/CT parameters were found to be prognostic in terms of survival or disease control.}

Issues regarding prognosis of locally advanced adenocarcinoma (AC) and SCC of the cervix have often been raised in the literature. The SCC and AC have many histological and genetics differences what has impact on cell metabolism, treatment response and prognosis. In some reports, the clinical outcome of these two subgroups of patients varied by 10% in favor of SCC [3,4]. Huang also reported a lower five-year relapse-free survival rate for 148 patients with AC [5,6]. In early advanced disease, there is a significant difference of 6% in 10-year DFS and 8% in 10-year OS between SCC and AC pts in favor of SCC [7,8]. Additionally, there was evidence SUV\textsubscript{max} is higher in squamous cell carcinomas compared to other histopathological diagnosis [9,10]. Therefore, for clarity of analysis, we focused on the very homogenous SCC tumors and parameters in relation to OS, DMFS, DFS and LC (Graph 1) [11].

There is a new clinical FIGO classification for involved PLN, and it is still unclear whether IIIC1 patients should be treated differently. We analyzed patients who were qualified for treatment according to the previous long-valid classification and we did not observe the influence of FIGO stage of primary tumor on OS, DMFS, DFS and even LC (Table 3). Therefore, our data supports the new FIGO classification for this group of patients. In our FIGO IIIC1 group, patients with higher SUV\textsubscript{max} (≥12.6, Graph 2A) and SUV\textsubscript{mean} (≥7.6, Graph 2B) lived longer. Moreover, these patients were less likely to have distant metastases, which probably resulted in the fact that we did not observe this relationship in DFS. The negative prognostic value of SUV\textsubscript{max} was evaluated in the study of Kidd et al., who showed in a predictive model for CC that SUV\textsubscript{max} was insignificant for OS (HR 1.009 and 95% confidence interval was 0.977–1.042), but significant for recurrence-free survival (RFS) (HR 1.033 and 95% confidence interval was 1.005–1.062). In another work of 93 patients, the significance of primary SUV\textsubscript{max} on both RFS and OS was confirmed [12]. However, this study presented some limitations, such as varying histopathologic status. Furthermore, only 33 patients presented active PLN in \[^{18}\text{F}]\text{FDG PET/CT. To metastasize to the lymph nodes, the tumor must undergo many genetic changes, which can significantly affect cell metabolism [13]. Perhaps this effect was observed in the \[^{18}\text{F}]\text{FDG PET/CT scans in our patients. It was partly confirmed by works that also did not observe the impact of high SUV\textsubscript{max} or SUV\textsubscript{mean} on patient prognosis. Yoo et al. looked for prognostic values in FDG PET/CT among 73 CC patients. Neither SUV\textsubscript{max} nor SUV\textsubscript{mean} of primary tumors correlated with disease-free survival or progression-free survival. In his work only TLG ≥7600 with HR 2.981 obtained from nuclear imaging resulted in multivariate analysis as prognostic factor.}
Imaging is the cornerstone in diagnosis, has a vast potential, and could allow for visualization of different biological processes all together within the entire tumor [14]. Several studies have indicated the tumor hypoxia as an adverse factor in cancer treatment and its association with poor outcome in CC. It can be visualized with $^{18}$F Fluoromisonidazole PET/CT or MRI [15,16]. Different biological characteristics of the tumor, e.g., blood supply, fibrosis, angiogenesis, coexist with tumor hypoxia and represent the heterogeneity of microenvironment conditions [17–19]. They are of interest because they are often associated with aggressiveness in growth or sensitivity to a specific therapy. Another interesting approach is shown in the work of Hillestad et al., where the distribution of different hypoxia levels on dynamic contrast enhanced (DCE) MRI within the CC tumor could distinguish different prognosis [20]. It would be of added value to correlate information from perfusion-weighted MRI and to visualize perfusion of FDG PET CT, which provides information on blood perfusion and glucose metabolism of the tumor. An important complementary study is gene-based classification, which along with imaging data has been shown to predict PFS significantly better in CC [17]. Gene expression signature for assessing hypoxia-related treatment resistance could be used with imaging information to personalize treatment [21]. Moreover, through comprehensive molecular, proteomic, and integrative profiling there is an insight into the biological diversity of CC.

Some authors also highlight the prognostic importance of volumetric parameters. In our study, the median TLG was 245.64 (range 26–1667), and patients with higher TLG unexpectedly lived longer ($p < 0.05$). The effect of TLG on DFS or LC was nonsignificant. Such results are to be expected, because TLG is partly dependent on SUVs. Hong et al. showed that high TLG of the primary lesion is predictive for recurrence-free survival (RFS) in patients with CC. They showed the outcome with only 20 months median follow up of multivariate analysis for recurrence-free survival with TLG $\leq$215.02 vs. >215.02, HR was 10.172 (95% CU, 1.246–83.044). A negative association on survival with higher MTV revealed a study on 120 pts [22]. All patients included in the study had SCC histopathology, which was a rarity. Unfortunately, the authors did not include nodal status, and treatment types were different. In our homogenous group tumor MTV was not statistically relevant ($p > 0.05$, Table 3) [23].

Lymph node status is known to be a strong independent negative prognostic factor in cervical cancer. The question arises as to whether the LN status is the factor driving the prognosis or it is still the characteristics and the potential for aggressive growth of primary tumor. It seems that promoting the metastatic spread of tumor cells is determined by the nature of the primary lesion. We did not observe any impact of clinical and $^{18}$F FDG PET/CT parameters of positive lymph nodes on OS, DMFS, LC DFS (Table 3). Similar results were found in the sub-analysis of 33 patients in the work of Voglimacci et al., which showed the leading role of primary tumor in the group with already defined positive PLN [13].

Our study has some limitations. Despite the retrospective nature and full insight into the history of the disease, there is some missing information in pathology reports like grading or Ki-67 level, HPV status. To reduce the potential error resulting from the analysis of the study in one center, PET images were analyzed by two independent professionals, a specialist in nuclear medicine and RTT experienced in gynecology oncology.

Concentrating research efforts on identifying specific factors in a noninvasive way before treatment may lead to tailor the right treatment and thus to a reduction in mortality for many cancer patients. Cervical AC is clearly different from SCC based on its molecular pathogenesis, histology, and clinic. Therefore, it should not be analyzed with SCC data, which is underlined by our findings, which show that the high SUV$_{\text{max}}$, SUV$_{\text{mean}}$ and TLG is linked with longer OS. This can suggest that tumors with high SUV values respond better to radiochemotherapy. Additionally, patients in our group with high metabolic activity have not developed distant metastasis. This phenomenon warrants further study.
5. Conclusions

In FIGO IIIC1, locally advanced cervical cancer patient population and SCC pathology treated with definitive RTCT high SUV_{mean}, SUV_{max} and TLG of the primary tumor were linked with longer OS. These features should be analyzed in an adaptive approach to treatment. Lower SUV_{mean} and SUV_{max} were linked with shorter DMFS. None of the nodal [^{18}F]FDG PET/CT parameters influenced OS, DFS, DMFS and LC.

Supplementary Materials: The following are available online at: https://www.mdpi.com/article/10.3390/diagnostics11040714/s1, FIGO Staging 2018, Table S1. FDG PET CT parameters of patients free of disease, Table S2. FDG PET CT parameters of patients with recurrence.

Author Contributions: Authorship contributions are listed as follows: conception and design of study: E.B.; acquisition of data: E.B., P.C., A.K., A.R. and W.C.; analysis and/or interpretation of data: E.B. and W.B.; drafting the manuscript: E.B. and W.B.; revising the manuscript critically for important intellectual content: E.B., W.B., P.C., A.R. and W.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was submitted to the local Ethical Committee. According to Polish regulations, the decision was that it does not require approval of the Ethical Committee.

Informed Consent Statement: Ethical review and approval were waived for this study. This study was submitted to the local Ethical Committee. According to Polish regulations, the decision was that it does not require approval of the Ethical Committee.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Arbyn, M.; Weiderpass, E.; Bruni, L.; de Sanjose, S.; Saraiya, M.; Ferlay, J.; Bray, F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health 2020, 8, e191–e203. [CrossRef]
2. Cegla, P.; Burchardt, E.; Wierczoslawksa, E.; Roszak, A.; Cholewinski, W. The effect of different segmentation methods on primary tumour metabolic volume assessed in 18F-FDG-PET/CT in patients with cervical cancer, for radiotherapy planning. Wspolczesna Onkol. 2019, 23, 183–186. [CrossRef]
3. Zhou, J.; Zhang, W.-W.; Wu, S.-G.; He, Z.-Y.; Sun, J.-Y.; Yang, G.-F.; Li, F.-Y. The prognostic value of histologic subtype in node-positive early-stage cervical cancer after hysterectomy and adjuvant radiotherapy. Int. J. Surg. 2017, 44, 1–6. [CrossRef]
4. Fujiwara, K.; Monk, B.; Devouassoux-Shisheboran, M. Adenocarcinoma of the Uterine Cervix: Why is it different? Curr. Oncol. Rep. 2014, 16, 416. [CrossRef] [PubMed]
5. Chen, J.-L.-Y.; Huang, C.-Y.; Huang, Y.-S.; Chen, R.-J.; Wang, C.-W.; Chen, Y.-H.; Cheng, J.-C.-H.; Cheng, A.-L.; Kuo, S.-H. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet. Gynecol. Scand. 2014, 93, 661–668. [CrossRef] [PubMed]
6. Galic, V.; Herzog, T.J.; Lewin, S.N.; Neugut, A.I.; Burke, W.M.; Lu, Y.-S.; Hershman, D.L.; Wright, J.D. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol. Oncol. 2012, 125, 287–291. [CrossRef] [PubMed]
7. Huang, Y.-T.; Wang, C.-C.; Tsai, C.-S.; Lai, C.-H.; Chang, T.-C.; Chou, H.-H.; Lee, S.P.; Hong, J.-H. Clinical Behaviors and Outcomes for Adenocarcinoma or Adenosquamous Carcinoma of Cervix Treated by Radical Hysterectomy and Adjuvant Radiotherapy or Chemoradiotherapy. Int. J. Radiat. Oncol. 2012, 84, 420–427. [CrossRef]
8. Lai, C.-H.; Hsueh, S.; Hong, J.-H.; Chang, T.-C.; Tseng, C.-J.; Chou, H.-H.; Huang, K.-G.; Lin, J.-D. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int. J. Gynecol. Cancer 1999, 9, 28–36. [CrossRef]
9. Park, J.-Y.; Kim, D.-Y.; Kim, J.-H.; Kim, Y.-M.; Nam, J.-H.; Kim, Y.-T. Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br. J. Cancer 2010, 102, 1692–1698. [CrossRef]
10. Schiffman, M.H.; Hildesheim, A. Cervical Cancer. Cancer Epidemiol. Prev. 1996, 2, 1090–1116. [CrossRef]
11. Kidd, E.A.; Spencer, C.R.; Huettrner, P.C.; Siegel, B.A.; Dehdashti, F.; Rader, J.S.; Grigsby, P.W. Cervical cancer histology and tumor differentiation affect18F-fluorodeoxyglucose uptake. Cancer 2009, 115, 3548–3554. [CrossRef] [PubMed]
12. Kidd, E.A.; El Naqa, I.; Siegel, B.A.; Dehdashti, F.; Grigsby, P.W. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol. Oncol. 2012, 127, 136–140. [CrossRef] [PubMed]
13. Voglimacci, M.; Gabiache, E.; Lusque, A.; Ferron, G.; Ducassou, A.; Querleu, D.; Motton, S.; Chantalat, E.; Courbon, F.; Martinez, A. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: Can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring? *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 1551–1559. [CrossRef] [PubMed]

14. Yoo, J.; Choi, J.Y.; Moon, S.H.; Bae, D.S.; Park, S.B.; Choe, Y.S.; Lee, K.H.; Kim, B.T. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography. *Int. J. Gynecol. Cancer* 2012, 22, 1226–1233. [CrossRef] [PubMed]

15. Höckel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schäffer, U.; Vaupel, P. Association between Tumor Hypoxia and Malignant Progression in Advanced Cancer of the Uterine Cervix1. *Cancer Res.* 1996, 56, 4509–4515. [PubMed]

16. Hompland, T.; Fjeldbo, C.; Lyng, H. Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter. *Cancers* 2021, 13, 499. [CrossRef] [PubMed]

17. Höckel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schäffer, U.; Vaupel, P. Association between Tumor Hypoxia and Malignant Progression in Advanced Cancer of the Uterine Cervix1. *Cancer Res.* 1996, 56, 4509–4515. [PubMed]

18. Rajendran, J.G.; Krohn, K.A. F-18 Fluoromisonidazole for Imaging Tumor Hypoxia: Imaging the Microenvironment for Personalized Cancer Therapy. *Semin. Nucl. Med.* 2015, 45, 151–162. [CrossRef]

19. Stieb, S.; Elefteriou, A.; Warnock, G.; Guckenberger, M.; Riesterer, O. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 2201–2217. [CrossRef]

20. Schlenger, K.; Höckel, M.; Mitze, M.; Schäffer, U.; Weikel, W.; Knapstein, P.G.; Lambert, A. Tumor Vascularity—A Novel Prognostic Factor in Advanced Cervical Carcinoma. *Gynecol. Oncol.* 1995, 59, 57–66. [CrossRef]

21. Fjeldbo, C.S.; Hompland, T.; Hillestad, T.; Aarnes, E.-K.; Günther, C.-C.; Kristensen, G.B.; Malinen, E.; Lyng, H. Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity. *EBioMedicine* 2020, 57, 102841. [CrossRef] [PubMed]

22. Hong, J.H.; Jung, U.S.; Min, K.J.; Lee, J.K.; Kim, S.; Eo, J.S. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer. *Nucl. Med. Commun.* 2016, 37, 843–848. [CrossRef] [PubMed]

23. Pinho, D.F.; King, B.; Xi, Y.; Albuquerque, K.; Lea, J.; Subramaniam, R.M. Value of Intratumoral Metabolic Heterogeneity and Quantitative18F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer. *Am. J. Roentgenol.* 2020, 214, 908–916. [CrossRef] [PubMed]